We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+6.1%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$836M
AUM Growth
-$103M
Cap. Flow
-$104M
Cap. Flow %
-12.49%
Top 10 Hldgs %
84.58%
Holding
23
New
1
Increased
6
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
DERM
Dermira, Inc.
DERM
+$23.9M
2
VRNA
Verona Pharma
VRNA
+$9.81M
3
AKBA icon
Akebia Therapeutics
AKBA
+$6.87M
4
FLXN
Flexion Therapeutics, Inc.
FLXN
+$2.13M
5
IVTY
Invuity, Inc
IVTY
+$353K

Top Sells

Rank Stock Value
1
IRTC icon
iRhythm Holdings
IRTC
+$76.1M
2
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$68.2M
3
OBSV
ObsEva SA Ordinary Shares
OBSV
+$2.48M
4
APEN
Apollo Endosurgery, Inc.
APEN
+$857K
5
HTGM
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
+$209K

Sector Composition

Rank Sector Weight
1 Healthcare 93.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INGN icon
1
Inogen
INGN
$167M
$339M 40.52%
3,549,320
– –
ANAB icon
2
AnaptysBio
ANAB
$1.6B
$72.6M 8.69%
3,033,504
– –
XLRN
3
DELISTED
Acceleron Pharma
XLRN
$47.2M 5.65%
1,553,937
– –
SPNC
4
DELISTED
Spectranetics Corp
SPNC
$45.6M 5.46%
1,187,917
+8,795
+0.7% +$254K
DERM
5
DELISTED
Dermira, Inc.
DERM
$44.7M 5.35%
1,534,664
+786,424
+105% +$23.9M
CRVS icon
6
Corvus Pharmaceuticals
CRVS
$1.1B
$39.3M 4.7%
3,244,046
+20,000
+0.6% +$214K
RARX
7
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$38.1M 4.56%
2,031,562
– –
FLXN
8
DELISTED
Flexion Therapeutics, Inc.
FLXN
$30.3M 3.63%
1,500,000
+102,282
+7% +$2.13M
AKBA icon
9
Akebia Therapeutics
AKBA
$327M
$26.1M 3.12%
1,814,289
+542,042
+43% +$6.87M
NBRV
10
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$24.4M 2.92%
9,306
– –
OBSV
11
DELISTED
ObsEva SA Ordinary Shares
OBSV
$23.2M 2.77%
2,710,760
-333,333
-11% -$2.48M
MRUS
12
DELISTED
Merus
MRUS
$22.4M 2.67%
1,410,417
– –
KALV
13
DELISTED
KalVista Pharmaceuticals
KALV
$21.4M 2.56%
2,901,927
– –
RETA
14
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$18.8M 2.24%
592,794
-2,774,969
-82% -$68.2M
APEN
15
DELISTED
Apollo Endosurgery, Inc.
APEN
$10.7M 1.28%
1,351,972
-105,000
-7% -$857K
IVTY
16
DELISTED
Invuity, Inc
IVTY
$9.89M 1.18%
1,363,848
+45,400
+3% +$353K
VRNA
17
DELISTED
Verona Pharma
VRNA
$8.64M 1.03%
+740,740
New +$9.81M
WMGIZ
18
DELISTED
Wright Medical Group, Inc. Contingent Value Right
WMGIZ
– –
0
– –
CRSP icon
19
CRISPR Therapeutics
CRSP
$4.58B
$3.58M 0.43%
223,317
– –
HTGM
20
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$3.27M 0.39%
6,836
-276
-4% -$209K
XENE icon
21
Xenon Pharmaceuticals
XENE
$6.32B
$402K 0.05%
127,563
– –
IRTC icon
22
iRhythm Holdings
IRTC
$3.59B
– –
-2,024,448
Closed -$76.1M
OPK icon
23
Opko Health
OPK
$921M
– –
-259
Closed -$2K

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.24B AUM 28.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
WTA
Washington Trust Advisors Wellesley, Massachusetts $1.24B AUM 22.58% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Novo Holdings A/S's Q2 2017 Portfolio in Review

As of Q2 2017, Novo Holdings A/S held 23 positions worth $836M, down 11% from $939M the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Novo Holdings A/S withdrew a net $104M in Q2 2017, closing 2 positions and reducing 4 holdings. Its most notable exit was iRhythm Holdings, an estimated $76.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 97% a quarter earlier.

Against the trend, Novo Holdings A/S opened a new position in Verona Pharma worth $8.64M.

  • Novo Holdings A/S's largest Q2 2017 buy was Verona Pharma: 740,740 shares worth $8.64M.
  • Novo Holdings A/S added most to Dermira, Inc. in Q2 2017, an estimated $23.9M increase.
  • Novo Holdings A/S's biggest Q2 2017 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $68.2M.
  • Novo Holdings A/S fully exited iRhythm Holdings in Q2 2017, selling an estimated $76.1M.
  • Novo Holdings A/S's ten largest holdings make up 85% of its $836M portfolio in Q2 2017.
  • Novo Holdings A/S opened 1 new position and closed 2 in Q2 2017.
  • Novo Holdings A/S's portfolio value fell 11% quarter-over-quarter to $836M.

Based on Novo Holdings A/S's 13F filing for Q2 2017, filed 14 Aug 2017.